Allergy Diagnostics Market Set to Reach USD 13.68 Billion by 2032 Growing at a CAGR of 12.06% – SNS Insider
As per S&S Insider Research, the global allergy diagnostics market growth is driven by increasing allergy prevalence, advanced testing technologies, and rising demand for precision diagnostics.
Austin, Oct. 13, 2025 (GLOBE NEWSWIRE) — Allergy Diagnostics Market Size & Growth Analysis
According to SNS Insider, the global Allergy Diagnostics Market was valued at USD 4.91 billion in 2023 and is projected to reach USD 13.68 billion by 2032, expanding at a CAGR of 12.06% over the forecast period. The growth is attributed to the growing incidence of allergies, rising awareness for early diagnosis, and available advanced diagnostic testing devices.
US is the largest market, owing to a well-established health care infrastructure, favorable reimbursement policies and wide acceptance of in vitro diagnostic testing in the region. Rise in environmental factors, shift in lifestyle and surge in patient awareness drive the demand in hospital-based labs, diagnostic centers, and research institute.
Increasing R&D investments, more sensitive testing kits, and the development of broader range of clinical applications will define the market landscape.
Get free Sample Report of Allergy Diagnostics Market: https://www.snsinsider.com/sample-request/4454
Major Players in the Allergy Diagnostics Market Include:
- Thermo Fisher Scientific, Inc. – ImmunoCAP, Phadia 250, Phadia 500
- DASIT Group SPA – Allergen Specific IgE Tests
- AESKU.GROUP GmbH – AESKU.DIA System, AESKU.RAPID Tests
- Astellas Pharma Inc. – Allergic Rhinitis Treatment (e.g., Astelin, Astepro)
- Epigenomics AG – Epi proLung
- Sun Pharmaceutical Industries Ltd – Ozel (oral antihistamine for allergy treatment)
- Teva Pharmaceutical Industries Ltd. – Qnasl, ProAir HFA
- Pfizer, Inc. – Xolair
- AbbVie, Inc. – Rinvoq
- Lincoln Diagnostics, Inc. – Linco Interdermal Test System, Linco Allergen Extracts
Allergy Diagnostics Market Report Scope
| Report Attributes | Details |
| Market Size in 2023 | USD 4.91 Billion |
| Market Size by 2032 | USD 13.68 Billion |
| CAGR | CAGR of 12.06 % From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Key Segments | By Type (Consumables, Instruments, Services)
By Test Type (In Vivo Test, In Vitro Test) By Allergen, (Inhaled Allergens, Food Allergens, Drug Allergens, and Other Allergens) By End-User (Hospital-based Laboratories & Clinics, Diagnostic Laboratories, Academic Research Institutes) |
| Regional Analysis/Coverage | North America (US, Canada), Europe (Germany, UK, France, Italy, Spain, Russia, Poland, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN Countries, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Mexico, Colombia, Rest of Latin America). |
Allergy Diagnostics Market Key Segments
By Type
Consumables dominated the allergy diagnostics market in 2023. This category consists of reagents, test kits and other consumables used in testing. Their repeated use for every test ensures a steady stream of revenue. The growing prevalence of allergies worldwide has contributed substantially to an uptick in consumption of these products at hospitals, clinics, and standalone laboratories.
Considering the continued introduction of rapid and multiplex allergen panels, this segment will continue to strengthen its position. These companies continue to develop highly sensitive kits, automation-friendly formats and increased precision.
By Test Type
In vitro test was the leading segment in 2023, with a market share of 54.23%. This test measure allergen-specific IgE levels and it has high specificity and predictive value.
An increase in food allergies globally, like those involving egg, milk, wheat and peanuts, is driving adoption. For instance, according to Food Allergy Research and Education 2022 numbers, about 2.8 million Americans were estimated to have an egg allergy, while around 2.5 million had a wheat allergy. Enhanced by growing prevalence rates, in vitro testing remains the gold standard in accurate and non-invasive diagnosis.
By Allergen
Inhaled allergens dominated the market, accounting for 48.68% in 2023; this segment is driven by high incidence of respiratory allergies due to industrialization, urban smog, and seasonal pollens. Facts (from the Allergy and Asthma Foundation of America) in 2021 is that over 81 million Americans were impacted by seasonal AR, including adults as well as children.
With the increase in pollution (global) and climate change, the rate of allergies is expected to accelerate across the globe.
By End User
The hospital-based laboratories and clinic’s segment accounted for the highest market share in 2023 at 32.65%. These are the initial source of care for allergy sufferers. Their wide diagnosis capabilities and integrated treatment schemes make them indispensable market factors.
Growth in this segment is further backed by increasing availability of sophisticated testing platforms and widespread insurance coverage in hospitals.
Buy the Allergy Diagnostics Market Report Now: https://www.snsinsider.com/checkout/4454
Regional Analysis
North America led the global allergy diagnostics market in 2023, accounting for 38.21% of total revenue. This leadership is credited to robust healthcare infrastructure, broader insurance coverage and more focus on preventive care. Thanks to the reimbursement rates being favourable and clearance of sophisticated test kits by regulatory authorities help the market grow in this region.
Asia Pacific is expected to witness the fastest growth owing to increasing health care expenditure, rising environmental pollution and growing awareness regarding allergy diseases. Increasing availability of allergy testing in developing economies, such as India and China, alongside emergence of cost-effective biosimilars and digital health tools will further facilitate utilization of these devices across the region.
Recent Developments in the Allergy Diagnostics Market
- March 2025 – Thermo Fisher Scientific introduced a next-generation multiplex allergy testing platform, improving diagnostic speed and sensitivity.
- February 2025 – Siemens Healthineers launched a new allergy testing system integrating AI-driven analytics for faster interpretation.
- January 2025 – Eurofins Scientific expanded its allergy diagnostics portfolio with rapid home testing solutions.
- December 2024 – Omega Diagnostics announced a strategic collaboration to develop point-of-care testing kits for emerging markets.
- November 2024 – Hycor Biomedical secured FDA clearance for its fully automated allergy testing system.
Access Complete Report Details of Allergy Diagnostics Market Analysis & Outlook: https://www.snsinsider.com/reports/allergy-diagnostics-market-4454
[For more information or need any customization research mail us at [email protected]]
About Us:
S&S Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
CONTACT: Contact Us: Rohan Jadhav - Principal Consultant Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK) Email: [email protected]
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. NewIndiaObserver.com takes no editorial responsibility for the same.